Cerevel Therapeutics Holdings Inc (FRA:673)

€ 23.6 0 (0%) Market Cap: 7.57 Bil Enterprise Value: 7.13 Bil PE Ratio: 0 PB Ratio: 14.49 GF Score: 20/100

Abbvie Inc To Acquire Cerevel Therapeutics Transcript
Dec 07, 2023
Q3 2023 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Nov 01, 2023

€22.2 (+2.78%)

Earnings
Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Aug 02, 2023

€27.4

Earnings
Cerevel Therapeutics Holdings Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
May 03, 2023

€27.6 (+8.66%)

Earnings
Cerevel Therapeutics Holdings Inc at Stifel CNS Days (Virtual) Transcript
Mar 29, 2023
Cerevel Therapeutics Holdings Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Q4 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Feb 22, 2023

€23.4

Earnings
Cerevel Therapeutics Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Nov 08, 2022

Earnings
Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Q2 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Aug 01, 2022

Earnings
Q1 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
May 10, 2022

Earnings
Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Cerevel Therapeutics Holdings Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 08, 2021
Cerevel Therapeutics Holdings Inc R&D Event Transcript
Jan 28, 2021

Q1 2023 Cerevel Therapeutics Holdings Inc Earnings Call Transcript

May 03, 2023 / 12:00PM GMT

Release Date Price: €27.6 (+8.66%)

Transcript 10-Q8-K

Operator

Good morning, and welcome to Cerevel Therapeutics First Quarter Financial Results Conference Call. (Operator Instructions) Please note that this call may be recorded.

I will now hand the call over to Matt Calistri, Vice President of Investor Relations.

Matthew Calistri

Cerevel Therapeutics Holdings, Inc. - VP of IR

Thank you. Good morning, everyone. We appreciate you joining us for our first quarter 2023 earnings call. On today's call, you'll be hearing from Dr. Tony Coles, our Chairperson and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Mark Bodenrader, our Interim Chief Financial Officer.

During our call today, please refer to our press release from this morning detailing our first quarter 2023 performance, as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to, among other things, the potential attributes and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.